Company intelligence / Profile preview

AnewPharma Company, Ltd.

Ownership: Private
Development stage: Preclinical

Overview

AnewPharma is focused on the development of the targeted therapy CM082 (vorolanib). Financial data from 2016 showed operating loss of CNY 13.9 million and net loss of CNY 10.9 million with no revenue reported.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Partnerships

Betta Pharmaceuticals Co., Ltd.

Beyond the preview

Go deeper on AnewPharma Company, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnewPharma Company, Ltd..

Explore the full profile